FRCPath Haem Part 1 EMQs-Oncology/Malignant Haem 516

Instructions: For each of the five patients below, select the SINGLE most appropriate first-line treatment option from the list. Each option may be used once, more than once or not at all.
Option | Treatment |
A | Venetoclax–Acalabrutinib (fixed duration) |
B | Venetoclax–Ibrutinib (fixed duration) |
C | Venetoclax–Obinutuzumab (fixed duration) |
D | Zanubrutinib (continuous) |
E | Acalabrutinib (continuous) |
F | Venetoclax (continuous monotherapy) |
Clinical scenarios
Question 1
A 58-year-old man is diagnosed with symptomatic CLL requiring treatment. He is otherwise fit and active. FISH and molecular testing demonstrate no del(17p) or TP53 mutation. He prefers a time-limited treatment approach.
Question 2
A 76-year-old woman presents with progressive lymphadenopathy, symptomatic splenomegaly and worsening anaemia. She has significant comorbidities and is considered unfit for intensive treatment. TP53 testing is normal. A fixed-duration treatment is preferred.
Question 3
A 64-year-old man has progressive CLL requiring first-line treatment. Molecular testing identifies a pathogenic TP53 mutation and FISH confirms del(17p). He has good performance status and no significant cardiovascular contraindications to BTK inhibitor therapy.
Question 4
A 71-year-old woman with treatment-requiring CLL has no TP53 disruption. She has a history of atrial fibrillation and is taking anticoagulation. A fixed-duration regimen is preferred following discussion of treatment options.
Question 5
A 68-year-old man has symptomatic CLL with del(17p) and a TP53 mutation. He has a significant bleeding history and poorly controlled hypertension, making BTK inhibitor therapy unsuitable. He requires treatment and venetoclax-based therapy is being considered.

Comments